In the Keynote 028 clinical trial (Pembrolizumab) enrolling 24 patients with PD-L1 positive endometrial cancer, the overall response rate was 13% and 6-month progression-free survival and overall survival were 19%, 68.8%, respectively [10]. Here, CD274 is linked to endometrial cancer.